Literature DB >> 8703826

Differential expression of CD3 and CD7 in T-cell malignancies: a quantitative study by flow cytometry.

L Ginaldi1, E Matutes, N Farahat, M De Martinis, R Morilla, D Catovsky.   

Abstract

Most T-cell antigens are expressed on normal and neoplastic T lymphocytes and for this reason it is not easy to distinguish between the immunophenotype of normal and malignant T cells. We have addressed this problem by comparing the levels of expression of CD3 and CD7 on T lymphocytes from 18 healthy donors with those of 61 cases of T-cell leukaemia using quantitative flow cytometry with a method that converts fluorescence intensity into number of antigen molecules per cell. Normal T lymphocytes expressed 124 +/- 25 CD3 and 20 +/- 3 x 10(3) CD7 molecules per cell. The mean CD3 values were significantly lower in all types of T-cell leukaemia than in normal T cells (P < 0.05), with the exception of Sezary syndrome. The lowest CD3 values were found in T-lymphoblastic leukaemia (T-ALL), 30 +/- 21 x 10(3), and adult T-cell leukaemia/lymphoma (ATLL), 38 +/- 31 x 10(3), followed by T-prolymphocytic leukaemia (T-PLL), 92 +/- 47 x 10(3), and granular lymphocyte leukaemia (GLL), 95 +/- 21 x 10(3). In contrast, the number of CD7 molecules was significantly higher in T-All, 35 +/- 7 x 10(3) (P < 0.01), and T-PLL, 29 +/- 12 x 10(3), than the normal controls (P < 0.01), whereas ATLL and GLL showed a low CD7 expression, 13 +/- 3 and 12 +/- 3 x 10(3), respectively. Our results show that the quantitative analysis of CD3 and CD7 and their combined evaluation may enable a distinction between normal and leukaemic T cells and could facilitate the monitoring of minimal residual disease. This study has also defined the T prolymphocyte as a cell of intermediate maturity between thymic derived and peripheral T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8703826     DOI: 10.1046/j.1365-2141.1996.d01-1720.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  13 in total

Review 1.  T-cell prolymphocytic leukemia.

Authors:  Claire E Dearden
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

2.  Levels of expression of CD19 and CD20 in chronic B cell leukaemias.

Authors:  L Ginaldi; M De Martinis; E Matutes; N Farahat; R Morilla; D Catovsky
Journal:  J Clin Pathol       Date:  1998-05       Impact factor: 3.411

3.  Minimal residual disease detection by flow cytometry in adult T-cell leukemia/lymphoma.

Authors:  Haipeng Shao; Constance M Yuan; Liqiang Xi; Mark Raffeld; John C Morris; John E Janik; Maryalice Stetler-Stevenson
Journal:  Am J Clin Pathol       Date:  2010-04       Impact factor: 2.493

4.  Effective flow cytometric phenotyping of cells using minimal amounts of antibody.

Authors:  Deepak Sharma; Mark R Eichelberg; Jill D Haag; Amanda L Meilahn; Matthew J Muelbl; Kathy Schell; Bart M G Smits; Michael N Gould
Journal:  Biotechniques       Date:  2012-07       Impact factor: 1.993

5.  Quantitative systems pharmacology modeling sheds light into the dose response relationship of a trispecific T cell engager in multiple myeloma.

Authors:  R E Abrams; K Pierre; N El-Murr; E Seung; L Wu; E Luna; R Mehta; J Li; K Larabi; M Ahmed; V Pelekanou; Z-Y Yang; H van de Velde; S K Stamatelos
Journal:  Sci Rep       Date:  2022-06-29       Impact factor: 4.996

Review 6.  Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management.

Authors:  Ryan A Wilcox
Journal:  Am J Hematol       Date:  2015-11-26       Impact factor: 10.047

7.  Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.

Authors:  Frans V Suurs; Grit Lorenczewski; Julie M Bailis; Sabine Stienen; Matthias Friedrich; Fei Lee; Bert van der Vegt; Elisabeth G E de Vries; Derk-Jan A de Groot; Marjolijn N Lub-de Hooge
Journal:  J Nucl Med       Date:  2021-04-30       Impact factor: 11.082

8.  A stable aberrant immunophenotype characterizes nearly all cases of cutaneous T-cell lymphoma in blood and can be used to monitor response to therapy.

Authors:  LaBaron T Washington; Yang O Huh; Linda C Powers; Madeleine Duvic; Dan Jones
Journal:  BMC Clin Pathol       Date:  2002-12-10

9.  Pediatric T-cell prolymphocytic leukemia with an isolated 12(p13) deletion and aberrant CD117 expression.

Authors:  Michael Bellone; Annika M Svensson; Ann-Leslie Zaslav; Silvia Spitzer; Marc Golightly; Mahmut Celiker; Youjun Hu; Yupo Ma; Tahmeena Ahmed
Journal:  Exp Hematol Oncol       Date:  2012-04-18

10.  Cutaneous T-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management.

Authors:  Alexandra C Hristov; Trilokraj Tejasvi; Ryan A Wilcox
Journal:  Am J Hematol       Date:  2021-08-02       Impact factor: 13.265

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.